Following the review of a large volume of international evidence, ATAGI have recommended that a single dose of Gardasil®9 (human papillomavirus vaccine) provides comparable protection in immune competent individuals compared with a 2 dose course. This recommendation is in line advice from the World Health Organization Strategic Advisory Group of Experts on Immunization (SAGE) and the UK’s Joint Committee on Vaccination Immunisation (JCVI). 

As a result, from February 6 2023, the National Immunisation program (NIP) moved to a single dose only Gardasil®9 schedule for immune competent adolescents aged 12-13 years. Individuals who have previously received 1 dose only and are waiting to receive their second dose no longer need to receive this dose, and are considered up to date. The Gardasil®9 catch-up program has also changed to a single dose only and has been extended to all individuals up 25 years and under.  

Immunocompromised individuals are still recommended to receive a 3 dose course of vaccination to ensure optimum protection.